A citation-based method for searching scientific literature

Albert Lai, Samir Kharbanda, Whitney B Pope, Anh Tran, Orestes E Solis, Franklin Peale, William F Forrest, Kanan Pujara, Jose A Carrillo, Ajay Pandita, Benjamin M Ellingson, Chauncey W Bowers, Robert H Soriano, Nils O Schmidt, Sankar Mohan, William H Yong, Somasekar Seshagiri, Zora Modrusan, Zhaoshi Jiang, Kenneth D Aldape, Paul S Mischel, Linda M Liau, Cameron J Escovedo, Weidong Chen, Phioanh Leia Nghiemphu, C David James, Michael D Prados, Manfred Westphal, Katrin Lamszus, Timothy Cloughesy, Heidi S Phillips. J Clin Oncol 2011
Times Cited: 306







List of co-cited articles
926 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
50

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
38

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
36

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
34

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
28

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
24

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan,[...]. Nature 2009
23

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
22

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. Am J Pathol 2009
678
22

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
780
21

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
20

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
19

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
18

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
17


Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
17

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, Shota Tanaka, Franziska Loebel, Nina Lelic, Dmitri Wiederschain, Olivier Bedel, Gejing Deng, Bailin Zhang,[...]. Cancer Cell 2015
221
17

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao,[...]. Cancer Cell 2011
17

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
793
17

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
478
16

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Houtan Noushmehr, Daniel J Weisenberger, Kristin Diefes, Heidi S Phillips, Kanan Pujara, Benjamin P Berman, Fei Pan, Christopher E Pelloski, Erik P Sulman, Krishna P Bhat,[...]. Cancer Cell 2010
14

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Brett E Johnson, Tali Mazor, Chibo Hong, Michael Barnes, Koki Aihara, Cory Y McLean, Shaun D Fouse, Shogo Yamamoto, Hiroki Ueda, Kenji Tatsuno,[...]. Science 2014
829
13

DNA methylation-based classification of central nervous system tumours.
David Capper, David T W Jones, Martin Sill, Volker Hovestadt, Daniel Schrimpf, Dominik Sturm, Christian Koelsche, Felix Sahm, Lukas Chavez, David E Reuss,[...]. Nature 2018
945
13

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma.
Philipp Kickingereder, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, Benedikt Wiestler. Sci Rep 2015
164
12

The definition of primary and secondary glioblastoma.
Hiroko Ohgaki, Paul Kleihues. Clin Cancer Res 2013
573
11

Probabilistic radiographic atlas of glioblastoma phenotypes.
B M Ellingson, A Lai, R J Harris, J M Selfridge, W H Yong, K Das, W B Pope, P L Nghiemphu, H V Vinters, L M Liau,[...]. AJNR Am J Neuroradiol 2013
135
11

Mutant IDH1 regulates the tumor-associated immune system in gliomas.
Nduka M Amankulor, Youngmi Kim, Sonali Arora, Julia Kargl, Frank Szulzewsky, Mark Hanke, Daciana H Margineantu, Aparna Rao, Hamid Bolouri, Jeff Delrow,[...]. Genes Dev 2017
202
11

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
11

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Sumihito Nobusawa, Takuya Watanabe, Paul Kleihues, Hiroko Ohgaki. Clin Cancer Res 2009
467
11

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
11

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
11

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
J A Carrillo, A Lai, P L Nghiemphu, H J Kim, H S Phillips, S Kharbanda, P Moftakhar, S Lalaezari, W Yong, B M Ellingson,[...]. AJNR Am J Neuroradiol 2012
179
10

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
Qianghu Wang, Baoli Hu, Xin Hu, Hoon Kim, Massimo Squatrito, Lisa Scarpace, Ana C deCarvalho, Sali Lyu, Pengping Li, Yan Li,[...]. Cancer Cell 2017
640
10

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Heidi S Phillips, Samir Kharbanda, Ruihuan Chen, William F Forrest, Robert H Soriano, Thomas D Wu, Anjan Misra, Janice M Nigro, Howard Colman, Liliana Soroceanu,[...]. Cancer Cell 2006
10

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Jason Beiko, Dima Suki, Kenneth R Hess, Benjamin D Fox, Vincent Cheung, Matthew Cabral, Nicole Shonka, Mark R Gilbert, Raymond Sawaya, Sujit S Prabhu,[...]. Neuro Oncol 2014
265
10

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Peppi Koivunen, Sungwoo Lee, Christopher G Duncan, Giselle Lopez, Gang Lu, Shakti Ramkissoon, Julie A Losman, Päivi Joensuu, Ulrich Bergmann, Stefan Gross,[...]. Nature 2012
516
10

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Christian Hartmann, Bettina Hentschel, Wolfgang Wick, David Capper, Jörg Felsberg, Matthias Simon, Manfred Westphal, Gabriele Schackert, Richard Meyermann, Torsten Pietsch,[...]. Acta Neuropathol 2010
520
10

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Maria E Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F Fernandez,[...]. Cancer Cell 2010
10

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Parker L Sulkowski, Christopher D Corso, Nathaniel D Robinson, Susan E Scanlon, Karin R Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K Sundaram, Denise C Hegan, Nathan R Fons,[...]. Sci Transl Med 2017
272
10

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
710
9

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Patrick S Ward, Jay Patel, David R Wise, Omar Abdel-Wahab, Bryson D Bennett, Hilary A Coller, Justin R Cross, Valeria R Fantin, Cyrus V Hedvat, Alexander E Perl,[...]. Cancer Cell 2010
9

Lactate dehydrogenase A silencing in IDH mutant gliomas.
Charles Chesnelong, Myriam M Chaumeil, Michael D Blough, Mohammad Al-Najjar, Owen D Stechishin, Jennifer A Chan, Russell O Pieper, Sabrina M Ronen, Samuel Weiss, H Artee Luchman,[...]. Neuro Oncol 2014
109
9

Analysis of the IDH1 codon 132 mutation in brain tumors.
Jörg Balss, Jochen Meyer, Wolf Mueller, Andrey Korshunov, Christian Hartmann, Andreas von Deimling. Acta Neuropathol 2008
749
9

IDH1 and IDH2 mutations in gliomas.
Adam L Cohen, Sheri L Holmen, Howard Colman. Curr Neurol Neurosci Rep 2013
316
9

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Tor-Christian Aase Johannessen, Joydeep Mukherjee, Pavithra Viswanath, Shigeo Ohba, Sabrina M Ronen, Rolf Bjerkvig, Russell O Pieper. Mol Cancer Res 2016
63
14

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
Yuchen Jiao, Patrick J Killela, Zachary J Reitman, Ahmed B Rasheed, Christopher M Heaphy, Roeland F de Wilde, Fausto J Rodriguez, Sergio Rosemberg, Sueli Mieko Oba-Shinjo, Suely Kazue Nagahashi Marie,[...]. Oncotarget 2012
393
9

T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Sohil H Patel, Laila M Poisson, Daniel J Brat, Yueren Zhou, Lee Cooper, Matija Snuderl, Cheddhi Thomas, Ana M Franceschi, Brent Griffith, Adam E Flanders,[...]. Clin Cancer Res 2017
128
9

Insulator dysfunction and oncogene activation in IDH mutant gliomas.
William A Flavahan, Yotam Drier, Brian B Liau, Shawn M Gillespie, Andrew S Venteicher, Anat O Stemmer-Rachamimov, Mario L Suvà, Bradley E Bernstein. Nature 2016
634
9

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Lukas Bunse, Stefan Pusch, Theresa Bunse, Felix Sahm, Khwab Sanghvi, Mirco Friedrich, Dalia Alansary, Jana K Sonner, Edward Green, Katrin Deumelandt,[...]. Nat Med 2018
177
9

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Felipe J Núñez, Flor M Mendez, Padma Kadiyala, Mahmoud S Alghamri, Masha G Savelieff, Maria B Garcia-Fabiani, Santiago Haase, Carl Koschmann, Anda-Alexandra Calinescu, Neha Kamran,[...]. Sci Transl Med 2019
87
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.